In a significant development for cancer research, two of the world’s largest pharmaceutical companies, AstraZeneca and Daiichi Sankyo, have entered a clinical collaboration with the biotech firm Summit Therapeutics. The three companies will jointly test Summit’s experimental antibody ivonescimab together with AstraZeneca‑Daiichi Sankyo’s investigational drug Datroway across multiple tumor types, beginning with a Phase III trial in first‑line triple‑negative breast cancer.
Collaboration details
The partnership builds on AstraZeneca’s recent $2 billion investment in Summit, which was made to accelerate a series of joint studies of promising cancer therapies. Under the agreement, each party will supply its own medicine—Datroway from AstraZeneca and Daiichi Sankyo, and ivonescimab from Summit—and share the costs of conducting the trial. All three companies will retain development and commercial rights to their respective products, ensuring that each can market its drug independently if the study proves successful.
Focus on triple‑negative breast cancer
Triple‑negative breast cancer (TNBC) is an aggressive form of the disease that lacks the hormone receptors commonly targeted by existing treatments. By testing Datroway and ivonescimab together as a first‑line option, the collaborators hope to improve response rates and overall survival for patients who currently have limited therapeutic choices. The Phase III trial will enroll patients across multiple sites worldwide, with enrollment expected to begin later this year.
Potential expansion to other cancers
While the initial study concentrates on TNBC, the agreement also outlines plans to evaluate the drug combination in other tumor types, including non‑small cell lung cancer. Both breast and lung cancers remain leading causes of cancer‑related mortality, and a successful combination therapy could represent a major advance in oncology.
Industry and patient impact
For the oncology community, the collaboration signals a growing trend toward multi‑company partnerships that pool resources and expertise to accelerate drug development. Patients stand to benefit from faster access to innovative treatments, especially in disease areas where existing options are inadequate.
Statements from the companies
AstraZeneca said the partnership reflects its commitment to delivering breakthrough medicines to patients in need. Daiichi Sankyo highlighted the importance of combining complementary technologies to address unmet medical needs, and Summit Therapeutics expressed optimism that the joint trial could generate meaningful data to support regulatory approval.
All three firms will continue to monitor trial progress closely and share updates with the medical community as results become available.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
